HealthQuill Clinical trials
Grey matter in the human brain may be linked to the start of adolescent smoking and nicotine addiction — a study that may have implications for prevention and treatment.
Health Research

MIT’s 40Hz gamma stimulation shows promise in slowing Alzheimer’s progression

HQ Team March 15, 2025: A decade of research at MIT’s Picower Institute for Learning and Memory has brought hope to millions battling.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Health Research

Aspirin shows promise in preventing cancer metastasis

HQ Team March 10, 2025: University of Cambridge scientists have uncovered the mechanism behind how aspirin could reduce the spread of certain cancers.

Read More
AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.
Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

 HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

Read More
AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.
Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

Read More
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according to a company statement.
Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.

Read More
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to a company statement.
Drugs Health Medical

Eli Lilly halts trials of investigational chronic kidney disease drug

Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.

Read More
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.

Read More